BioTime, Inc. (NYSEAMERICAN:BTX) shares rose 10.7% during mid-day trading on Monday . The company traded as high as $2.71 and last traded at $2.69. Approximately 2,355,300 shares were traded during mid-day trading, an increase of 338% from the average daily volume of 537,810 shares. The stock had previously closed at $2.43.
BTX has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of BioTime from a “buy” rating to a “hold” rating in a research note on Friday, December 22nd. Lake Street Capital initiated coverage on shares of BioTime in a research note on Friday, February 2nd. They issued a “buy” rating and a $8.00 price objective on the stock. Three analysts have rated the stock with a sell rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $5.75.
BioTime (NYSEAMERICAN:BTX) last posted its earnings results on Thursday, March 15th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $2.38 million. BioTime had a return on equity of 30.68% and a net margin of 828.55%.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.wkrb13.com/2018/04/02/biotime-btx-stock-price-up-10-7.html.
BioTime Company Profile
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.